2025
DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures
Leelatian N, Singh C, Bouffard R, Sundaram R, Diggins K, Sullivan W, Paradkar S, Omay Z, Mobley B, Gueble S, Vasquez J, Bindra R. DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures. Neuro-Oncology 2025, noaf199. PMID: 40887772, DOI: 10.1093/neuonc/noaf199.Peer-Reviewed Original ResearchDNA damage responseLow-grade gliomasGene expression patternsGene expressionDiffuse gliomasImaging Mass CytometryPoor survivalHigher abundanceSingle-cell heterogeneityAssociated with poor survivalClinical assessmentSingle-cell protein analysisDNA methylation profilesGlobal DNA methylation profilesIDH mutation statusDNA damage response defectsProliferative tumor cellsNovel treatment strategiesOutcome of gliomaEffector expressionMGMT statusMutation statusTumor levelsActive area of investigationMethylation profiles
2023
MGMT promoter methylation in 1p19q-intact gliomas
Kinslow C, Siegelin M, Iwamoto F, Gallitto M, Neugut A, Yu J, Cheng S, Wang T. MGMT promoter methylation in 1p19q-intact gliomas. Journal Of Neuro-Oncology 2023, 166: 73-78. PMID: 38114801, DOI: 10.1007/s11060-023-04515-z.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMGMT promoter methylationOverall survivalIDH-wildtypeMGMT statusAdjuvant temozolomideAnaplastic gliomasPromoter methylationAssociated with poor survivalAssociation of MGMTClinical efficacy of temozolomideIDH-mutant astrocytomasCox proportional hazards regression modelsIDH-wildtype gliomasKaplan-Meier methodWell-powered prospective studiesMGMT promoter statusEfficacy of temozolomideProportional hazards regression modelsInternational randomized phaseStandard-of-careHazards regression modelsCATNON trialAnaplastic astrocytomaCancer Database
2022
NIMG-80. A RADIOMICS-BASED MODEL PREDICTIVE OF OVERALL SURVIVAL IN GLIOBLASTOMA USING MULTI-INSTITUTIONAL PREOPERATIVE MRI SCANS
Kowalchuk R, Conte G, Crompton D, Cabreja R, Vega C, Moassefi M, Faghani S, Khosravi B, Vora S, Erickson B, Trifiletti D. NIMG-80. A RADIOMICS-BASED MODEL PREDICTIVE OF OVERALL SURVIVAL IN GLIOBLASTOMA USING MULTI-INSTITUTIONAL PREOPERATIVE MRI SCANS. Neuro-Oncology 2022, 24: vii183-vii183. DOI: 10.1093/neuonc/noac209.698.Peer-Reviewed Original ResearchPredictive of OSPreoperative MRI scansC-indexPredictive of decreased OSMRI scansRegions of contrast enhancementDate of surgeryKaplan-Meier analysisPost-contrast T1Median OSMGMT statusOS estimatesPostoperative imagingPrimary endpointMulti-institutional datasetClinical decision-makingAbstract PurposeConcordance indexFollow-upPrognostic abilityRadiomics-basedC-indicesNon-enhancedRadiomic featuresPatientsAssociation of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.Peer-Reviewed Original ResearchIDH-wt GBMAssociated with poor OSMethylation subclassesOverall survivalPoor OSIDH-wtMolecular subclassesRTK IAssociated with worse survivalAssociated with OSIDH-wildtype glioblastomaPotential survival benefitAssociation of hyperglycemiaAverage glucose valuesAverage glucoseStupp protocolDexamethasone doseMGMT statusSurvival benefitWorse survivalMesenchymal tumorsPerformance statusLow glucose levelsMGMT methylationMolecular subtypes
2021
NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Placantonakis D, Possemato R, Snuderl M. NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi154-vi154. PMCID: PMC8598635, DOI: 10.1093/neuonc/noab196.602.Peer-Reviewed Original ResearchIDH-wt glioblastomaAssociated with poor OSMethylation subclassesDexamethasone doseOverall survivalPoor OSIDH-wtMolecular subclassesAssociated with worse survivalRNA expressionIDH-wildtype glioblastomaPotential survival benefitDNA methylation clustersIsocitrate dehydrogenase (IDH)-wildtypeAssociated with survivalClinical next-generation sequencingPlasma glucose measurementsDNA methylation studiesAverage glucoseNext-generation sequencingStupp protocolMGMT statusMesenchymal tumorsPrognostic significanceSurvival benefit
2016
MPTH-01. ARE MUTATIONS IN MISMATCH REPAIR (MMR) GENES OUR NEXT BIOMARKER OF ALKYLATING AGENT INDUCED HYPERMUTATOR PHENOTYPE? PRELIMINARY RESULTS FROM THE IVY PRECISION TRIAL
Kuhn J, Chen R, Clarke J, Chang S, Cloughesy T, Colman H, Wen P, Mellinghoff I, Ligon K, de Groot J, Batchelor T, Omuro A, Taylor J, Butowski N, Halperin R, Tran N, Carpten J, Craig D, Byron S, Berens M, Prados M. MPTH-01. ARE MUTATIONS IN MISMATCH REPAIR (MMR) GENES OUR NEXT BIOMARKER OF ALKYLATING AGENT INDUCED HYPERMUTATOR PHENOTYPE? PRELIMINARY RESULTS FROM THE IVY PRECISION TRIAL. Neuro-Oncology 2016, 18: vi105-vi105. DOI: 10.1093/neuonc/now212.440.Peer-Reviewed Original ResearchIDH1 mutationMMR mutationsPRECISION trialHypermutator phenotypeMutation/lossClinical Trials ConsortiumHigh neoantigen loadRecurrent GBM tumorsWhole-exome sequencingMMR alterationsNext biomarkersPrior therapySpecific immunotherapyNeoantigen loadRecurrent GBMPhenotype patientsTumor boardMutational loadPatientsProgressive gliomasMGMT statusMLH1 mutationsGBM tumorsTherapeutic opportunitiesTumors
2007
Molecular genetic markers as predictors of response to chemotherapy in gliomas
Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Current Opinion In Oncology 2007, 19: 606-611. PMID: 17906460, DOI: 10.1097/cco.0b013e3282f075f3.Peer-Reviewed Original ResearchConceptsAnaplastic oligodendroglial tumorsLow-grade gliomasProspective trialMGMT statusOligodendroglial tumorsIndependent favorable prognostic factorFavorable prognostic factorRelevant prognostic markerPredictors of responsePromoter methylationTreatment of gliomaPredictor of chemosensitivityMGMT promoter methylationObjective responsePrognostic factorsRetrospective studyPrognostic markerSuch tumorsTreatment decisionsChromosome 1p/19q codeletionMGMT inactivationPredictive valueChemotherapyGliomasLow expression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply